CGX1321 in Liposome Formulation Enhances CGX1321 Tolerance and Decreased the Toxicity to Mice
H&E (A) and Alcian blue (B) staining of the vehicle and treated tumor samples. (C) Tumor growth was plotted by mean with SEM (n = 8). Tumor samples were from GA007 PDX mice, which were treated with 10 mL/kg liposome blank, 10 mg/kg CGX1321 in D5W, p.o., q.d., or 10 mg/kg CGX1321 in liposome, i.v., q.o.d., for 14 days. (D) Bodyweight changes were calculated before and after CGX1321 in D5W or liposome formulation treatments for 14 days (n = 8), ***p < 0.0001.